FI932695A0 - Angiotensin I Chyme Inhibitor in Inclusive Humans - Google Patents

Angiotensin I Chyme Inhibitor in Inclusive Humans

Info

Publication number
FI932695A0
FI932695A0 FI932695A FI932695A FI932695A0 FI 932695 A0 FI932695 A0 FI 932695A0 FI 932695 A FI932695 A FI 932695A FI 932695 A FI932695 A FI 932695A FI 932695 A0 FI932695 A0 FI 932695A0
Authority
FI
Finland
Prior art keywords
chyme
angiotensin
inclusive
humans
inhibitor
Prior art date
Application number
FI932695A
Other languages
Finnish (fi)
Other versions
FI932695A (en
Inventor
Dennis J Hoover
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI932695A0 publication Critical patent/FI932695A0/en
Publication of FI932695A publication Critical patent/FI932695A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI932695A 1992-06-12 1993-06-11 ANGIOTENSIN I KYMAS-INHIBITORER INKLUSIVE HUMANT HJAERTKYMAS FI932695A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89772392A 1992-06-12 1992-06-12

Publications (2)

Publication Number Publication Date
FI932695A0 true FI932695A0 (en) 1993-06-11
FI932695A FI932695A (en) 1993-12-13

Family

ID=25408314

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932695A FI932695A (en) 1992-06-12 1993-06-11 ANGIOTENSIN I KYMAS-INHIBITORER INKLUSIVE HUMANT HJAERTKYMAS

Country Status (5)

Country Link
EP (1) EP0644892A1 (en)
JP (1) JP2668003B2 (en)
CA (1) CA2137832C (en)
FI (1) FI932695A (en)
WO (1) WO1993025574A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524267D0 (en) * 1995-11-28 1996-01-31 Isis Innovation Enzyme inhibitor and method
BR9712023A (en) * 1996-09-10 1999-08-31 Thomae Gmbh Dr K Derived amino acids, drugs containing these compounds and processes for their preparation.
JP4080541B2 (en) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
SI0932617T1 (en) * 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
KR20000052775A (en) * 1996-10-25 2000-08-25 가마쿠라 아키오 Novel heterocyclic amide compounds and medicinal uses thereof
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2321146A1 (en) 1998-02-17 1999-08-19 Nippon Kayaku Kabushiki Kaisha Novel acetamide derivative and use thereof
CA2341195A1 (en) * 1998-08-20 2000-03-02 Mitsunori Waki Prophylactic or therapeutic composition for ocular circulation disorders
AU1414000A (en) * 1998-12-01 2000-06-19 Meiji Seika Kaisha Ltd. Sf2809-i, ii, iii, iv, v and vi substances exhibiting chymase-inhibiting activities
DE60034545T2 (en) 1999-11-01 2007-10-25 Asubio Pharma Co., Ltd. USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION
CA2368382A1 (en) 2000-02-22 2001-08-30 Suntory Limited Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient
CN1366461A (en) 2000-02-22 2002-08-28 三得利株式会社 Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as active ingredient
CA2365606A1 (en) 2000-02-22 2001-08-30 Suntory Limited Medicament for prevention or treatment of various diseases involving an increase in eosinophils chymase inhibitor as effective ingredient
WO2001083471A1 (en) * 2000-05-02 2001-11-08 Meiji Seika Kaisha, Ltd. Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
WO2002006280A2 (en) * 2000-07-13 2002-01-24 Millennium Pharamaceuticals, Inc. INHIBITORS OF FACTOR Xa
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
US20060217421A1 (en) 2003-05-09 2006-09-28 Hajimu Kurumatani Fortifier
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
EA017448B1 (en) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
SI2364309T1 (en) 2008-12-10 2015-03-31 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
KR20160005686A (en) 2013-03-15 2016-01-15 아칠리온 파르마세우티칼스 인코포레이티드 Sovaprevir polymorphs and methods of manufacture thereof
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
AU2017282651B2 (en) 2016-06-21 2021-08-12 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
ZA905737B (en) * 1989-07-26 1991-05-29 Merrell Dow Pharma Novel peptidase inhibitors
EP0587799B1 (en) * 1991-05-23 1999-07-07 Merrell Pharmaceuticals Inc. Inhibitors of cathepsin g and elastase for preventing connective tissue degradation

Also Published As

Publication number Publication date
WO1993025574A1 (en) 1993-12-23
EP0644892A1 (en) 1995-03-29
CA2137832C (en) 2000-09-26
JPH07507069A (en) 1995-08-03
FI932695A (en) 1993-12-13
JP2668003B2 (en) 1997-10-27
CA2137832A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
FI932695A0 (en) Angiotensin I Chyme Inhibitor in Inclusive Humans
NO932005D0 (en) Angiotensin II antagonists
FI20021195A (en) CDMA taajuusallokointi
DE69222931D1 (en) Excavator and application processes
NO942064D0 (en) inhibitors
DE69419995D1 (en) Attenuator
NO943025D0 (en) Third Party Load
DE69214428T2 (en) Excavator and application processes
FI943513A0 (en) 3-Phenylureidoazepin-2-ones and benzazepin-2-ones useful as cholecystokinin antagonists
ITMI921571A1 (en) AZACICLO AND AZABICICLO ALCHILIDEN IDROSSILAMINE
FI1031U1 (en) And troakar
DE59308210D1 (en) People passage
DK83692D0 (en) RELATIONS
KR930008914U (en) Protection block for waterway and slope
ATA83492A (en) DESTRUCTION
DE9312393U1 (en) Personal protection device
KR950008227U (en) Checkerboard
KR940026285U (en) Checkerboard
KR950005742U (en) Checkerboard
KR950010970U (en) Prefabricated checkerboard
ITMI931648A1 (en) AZACICLO AND AZABICICLO AMMIDI
DE59404785D1 (en) DEFENSE DEVICE
SE9203239D0 (en) In L-LIST
KR960003702U (en) Pendant and tie set using it
FI904U1 (en) In the construction of the construction site